5 Pharmaceutical Stocks to Buy According to Jim Simons’ Euclidean Capital

4. Denali Therapeutics Inc. (NASDAQ:DNLI)

Euclidean Capital’s Stake Value: $25.39 million

Percentage of Euclidean Capital’s 13F Portfolio: 5.93%

Number of Hedge Fund Holders: 22

Denali Therapeutics Inc. (NASDAQ:DNLI), a developer of therapeutic candidates for neurodegenerative diseases, has lost 32% since the beginning of the year. Despite significant gains, rating firms look bullish over Denali’s pipeline. Oppenheimer initiated coverage of Denali Therapeutics with an Outperform rating and $85 stock price target.